Cargando…
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab
INTRODUCTION: Infliximab is an effective treatment for inflammatory bowel disease (IBD). Studies differ regarding the influence of body mass index (BMI) on the response to infliximab, with the majority of studies indicating that increased BMI may be associated with a poorer response to Infliximab. H...
Autores principales: | Scaldaferri, Franco, D‘Ambrosio, Daria, Holleran, Grainne, Poscia, Andrea, Petito, Valentina, Lopetuso, Loris, Graziani, Cristina, Laterza, Lucrezia, Pistone, Maria Teresa, Pecere, Silvia, Currò, Diego, Gaetani, Eleonora, Armuzzi, Alessandro, Papa, Alfredo, Cammarota, Giovanni, Gasbarrini, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657978/ https://www.ncbi.nlm.nih.gov/pubmed/29073159 http://dx.doi.org/10.1371/journal.pone.0186575 |
Ejemplares similares
-
Infliximab does not increase colonic cancer risk associated to murine chronic colitis
por: Lopetuso, Loris R, et al.
Publicado: (2016) -
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2023) -
The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
por: Holleran, Grainne, et al.
Publicado: (2017) -
Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility
por: Scaldaferri, Franco, et al.
Publicado: (2013) -
Bariatric procedures and microbiota: patient selection and outcome prediction
por: Puca, Pierluigi, et al.
Publicado: (2021)